Bharat Biotech said according to the research, Covaxin "produced neutralising titres (meaning the concentration of antibodies) against all key emerging variants".
"There was a modest reduction in neutralization by a factor of 1.95 was observed against B.1.617 variant compared to vaccine variant (D614G). Despite this reduction, neutralising titre levels with B.1.617 remain above levels expected to be protective," read the excerpts highlighted by Bharat Biotech.
"Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap," tweeted Suchitra Ella, the co-founder and Joint Managing Director of Bharat Biotech.
Her tweet spurred questions on social media regarding the availability of Covaxin, which received emergency approval along with Oxford University's Covishield in January.
The vaccine was launched in clinical trial mode as its third phase of trial was pending.
There were also questions on inviting other companies to manufacture the vaccine amid the current shortage, which has slowed down vaccination in the country despite the ongoing, aggressive second wave of Covid driven by lethal variants of the virus.
The Centre has already assured that it is willing to scale up production by roping in other companies willing to manufacture the vaccine.
Source: foreign media